NCI Lung Cancer Mutation Consortium: Screening For Mutations Can Focus Therapy
Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival
OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent
Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study
First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors
Telatinib Demonstrates Positive Results in First-Line Treatment
Barret’s Less of a Risk Factor For Cancer of the Esophagus
New Abiraterone Acetate Results Show Greater Benefit Than Before
MGMT Gene Can Determine Disease Aggressiveness
Phase III Study: Lymphoseek Superior to Vital Blue Dye
Intensity Modulated Therapy Safer Than Three-Dimensional Radiation
Smokers Quitlines Found Effective Regardless of Recruitment Method
Study: Vismodegib Effective Where Surgery is Inappropriate
NCI-Approved Clinical Trials For The Month of June
FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”
FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors
Trending Stories
- Gynecology’s deadly surprise:
Cancers are frequently missed prior to routine procedures - Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities
- Rathmell announces new cancer screening network, new NCI virtual clinical trials office
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ASCO 2024 special awards go to: Winn, Bhatia, Dale, Siu, Pierce, Kantoff, Newman, Gopal, Mutebi, Feldman, Gorlick, Pietenpol, Abrahm, Giordano, Vaz-Luis